102 However, various groups are advocating for your incorporation of novel markers, like a complicated karyotype55 or epigenetic subsets, 27,28 into clinical follow. These novel prognostic and/or predictive products will have to be validated in cohorts of patients treated with focused brokers. This Web page hasn't been scanned in a https://dickk420iry8.bloggazzo.com/profile